Virus News and Research

Latest Virus News and Research

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.

9 Feb 2010

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract.

9 Feb 2010

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Novavax, Inc. announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains.

9 Feb 2010

Dana-Farber Cancer Institute and Sanford-Burnham Medical Research Institute sign license agreement with Genentech

Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses. These viruses include the strains for the current seasonal and H1N1 influenzas. Genentech and Roche also have a non-exclusive right to manufacture, develop and market diagnostic tests for group 1 influenza.

9 Feb 2010

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

Cerus Corporation announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells continued to circulate 24 hours following transfusion. The INTERCEPT red blood cell system is a pathogen inactivation treatment the company is developing to protect against transmission of infectious diseases through red blood cell transfusions. An estimated 70 million units of red blood cells are transfused worldwide each year.

9 Feb 2010

Alnylam Pharmaceuticals receives 'Notice of Allowance' from USPTO

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the “Soutschek and Manoharan” patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery.

9 Feb 2010

GeoVax Labs provides updates on HIV-1 vaccine trials

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today provided an update on its vaccine trials progress.

9 Feb 2010

Plant-produced antibodies can help prevent infection

The first head-to-head comparison of therapeutic monoclonal antibodies produced from plants versus the same antibodies produced from mammalian cells has shown that plant-produced antibodies can fight infection equally well.

9 Feb 2010

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

8 Feb 2010

Novavax to discontinue collaboration agreement with ROVI Pharmaceuticals

Novavax, Inc. announced today that the company has decided to discontinue negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals to develop Novavax's virus-like-particle (VLP)-based vaccines against influenza in the country of Spain.

8 Feb 2010

Smokers more likely to vaccinate their daughters against HPV

A parent's existing health habits or behaviors, like cigarette smoking, may influence the likelihood that they will have their daughters vaccinated against HPV.

8 Feb 2010

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

MDS Nordion, a global leader in providing products and services for medical imaging and radiotherapeutics, today announced that two of the largest health insurers in the United States have recently approved coverage of radioembolization to treat unresectable liver cancer, which includes the use of MDS Nordion's TheraSphere(R) treatment. The two insurance companies and their affiliates together serve more than one-quarter of Americans and do business in all 50 states.

6 Feb 2010

Majority of Americans believe flu outbreak is over; levels of concern continue to decline

The latest poll from researchers at the Harvard School of Public Health (HSPH) shows that almost half of Americans believe the H1N1 flu outbreak is over (44%), and levels of concern about getting sick with the virus continue to decline.

6 Feb 2010

Breakthrough discovery could help in developing a broad spectrum of antiviral drugs

Within a virus's tiny exterior is a store of energy waiting to be unleashed. When the virus encounters a host cell, this pent-up energy is released, propelling the viral DNA into the cell and turning it into a virus factory.

6 Feb 2010

New virology textbook treats viruses in the context of virus families

A new virology textbook published by ASM Press educates the reader by focusing on the families. Based on the author's experiences teaching virology for more than 35 years, Virology: Molecular Biology and Pathogenesis enables readers to develop a deep understanding of fundamental virology by emphasizing principles and discussing viruses in the context of virus families.

5 Feb 2010

Virginia Tech professor wins grant to formulate mathematical framework for flu prevention

An assistant professor with the Virginia Tech College of Engineering has won a $750,000 federal grant to formulate a mathematical framework that can track the spread of pandemics among populations and malware across wireless computer networks, as well as how a blackout occurring on one major power grid can cause a cascade of additional neighboring networks to fail.

5 Feb 2010

U.S. lawmakers introduce resolution condemning Uganda's anti-gay bill

U.S. lawmakers on Wednesday introduced a congressional resolution condemning an anti-gay bill before Uganda's parliament, "calling it an attack on human rights and an obstacle to battling HIV/AIDS," Agence France-Presse reports.

5 Feb 2010

Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Biota Holdings Limited today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009.

5 Feb 2010

Tecan Group, Enigma Diagnostics sign manufacturing and supply agreement for Enigma ML instruments

The Tecan Group, a leading global provider of laboratory instruments and solutions, and Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the signing of a manufacturing and supply agreement for Enigma's ML instruments.

From Tecan 5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Virus News and Research

Latest Virus News and Research

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Dana-Farber Cancer Institute and Sanford-Burnham Medical Research Institute sign license agreement with Genentech

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

Alnylam Pharmaceuticals receives 'Notice of Allowance' from USPTO

GeoVax Labs provides updates on HIV-1 vaccine trials

Plant-produced antibodies can help prevent infection

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Novavax to discontinue collaboration agreement with ROVI Pharmaceuticals

Smokers more likely to vaccinate their daughters against HPV

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

Majority of Americans believe flu outbreak is over; levels of concern continue to decline

Breakthrough discovery could help in developing a broad spectrum of antiviral drugs

New virology textbook treats viruses in the context of virus families

Virginia Tech professor wins grant to formulate mathematical framework for flu prevention

U.S. lawmakers introduce resolution condemning Uganda's anti-gay bill

Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Tecan Group, Enigma Diagnostics sign manufacturing and supply agreement for Enigma ML instruments

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in